JP2022525099A5 - - Google Patents

Info

Publication number
JP2022525099A5
JP2022525099A5 JP2021554674A JP2021554674A JP2022525099A5 JP 2022525099 A5 JP2022525099 A5 JP 2022525099A5 JP 2021554674 A JP2021554674 A JP 2021554674A JP 2021554674 A JP2021554674 A JP 2021554674A JP 2022525099 A5 JP2022525099 A5 JP 2022525099A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
polynucleotide
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021554674A
Other languages
English (en)
Japanese (ja)
Other versions
JP7611844B2 (ja
JP2022525099A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/021916 external-priority patent/WO2020185796A1/en
Publication of JP2022525099A publication Critical patent/JP2022525099A/ja
Publication of JP2022525099A5 publication Critical patent/JP2022525099A5/ja
Application granted granted Critical
Publication of JP7611844B2 publication Critical patent/JP7611844B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021554674A 2019-03-11 2020-03-10 高アビディティwt1t細胞受容体とその使用 Active JP7611844B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962816746P 2019-03-11 2019-03-11
US62/816,746 2019-03-11
PCT/US2020/021916 WO2020185796A1 (en) 2019-03-11 2020-03-10 High avidity wt1 t cell receptors and uses thereof

Publications (3)

Publication Number Publication Date
JP2022525099A JP2022525099A (ja) 2022-05-11
JP2022525099A5 true JP2022525099A5 (cg-RX-API-DMAC7.html) 2023-03-17
JP7611844B2 JP7611844B2 (ja) 2025-01-10

Family

ID=70155376

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021554674A Active JP7611844B2 (ja) 2019-03-11 2020-03-10 高アビディティwt1t細胞受容体とその使用

Country Status (13)

Country Link
US (1) US12448430B2 (cg-RX-API-DMAC7.html)
EP (1) EP3938386A1 (cg-RX-API-DMAC7.html)
JP (1) JP7611844B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210138043A (cg-RX-API-DMAC7.html)
CN (1) CN113784978B (cg-RX-API-DMAC7.html)
AU (1) AU2020237043A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021017703A8 (cg-RX-API-DMAC7.html)
CA (1) CA3132845A1 (cg-RX-API-DMAC7.html)
EA (1) EA202192252A1 (cg-RX-API-DMAC7.html)
IL (1) IL286202A (cg-RX-API-DMAC7.html)
MX (1) MX2021010837A (cg-RX-API-DMAC7.html)
SG (1) SG11202109745PA (cg-RX-API-DMAC7.html)
WO (1) WO2020185796A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD3551221T2 (ro) 2016-12-08 2022-04-30 Immatics Biotechnologies Gmbh Noi receptori de celule T și imunoterapie cu utilizarea acestora
CR20230295A (es) * 2020-12-31 2023-07-27 Immatics Us Inc Polipéptidos cd8, composiciones y métodos de uso de estos
CN120112559A (zh) * 2022-10-28 2025-06-06 百奥赛图(北京)医药科技股份有限公司 抗wt1/hla抗体及其应用
WO2025029648A1 (en) * 2023-07-28 2025-02-06 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting loxhd1-associated disease
WO2025245169A1 (en) 2024-05-21 2025-11-27 Fred Hutchinson Cancer Center Immunotherapy cells equipped with a collagen-targeting payload
WO2026125718A1 (en) * 2024-12-13 2026-06-18 Immunoscape Pte. Ltd. Human t cell receptors and uses thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US5420032A (en) 1991-12-23 1995-05-30 Universitge Laval Homing endonuclease which originates from chlamydomonas eugametos and recognizes and cleaves a 15, 17 or 19 degenerate double stranded nucleotide sequence
US5792632A (en) 1992-05-05 1998-08-11 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
GB9518220D0 (en) 1995-09-06 1995-11-08 Medical Res Council Checkpoint gene
AU4932199A (en) 1998-07-31 2000-02-21 Haruo Sugiyama Cancer antigens based on tumor suppressor gene wt1 product
US8206965B2 (en) 2002-03-15 2012-06-26 Cellectis S.A. Hybrid and single chain meganucleases and use thereof
EP1550453B1 (en) 2002-09-12 2015-05-27 International Institute of Cancer Immunology, Inc. Cancer antigen peptide preparation
US20060206949A1 (en) 2003-01-28 2006-09-14 Sylvain Arnould Custom-made meganuclease and use thereof
GB0328363D0 (en) 2003-12-06 2004-01-14 Imp College Innovations Ltd Therapeutically useful molecules
PT1731605E (pt) 2004-03-31 2010-04-14 Int Inst Cancer Immunology Inc Péptidos antigénicos de cancro derivados de wt1
WO2006076678A2 (en) 2005-01-13 2006-07-20 The Johns Hopkins University Prostate stem cell antigen vaccines and uses thereof
DK3246403T3 (da) 2005-10-18 2020-10-26 Prec Biosciences Rationelt designede meganucleaser med ændret sekvens-specificitet og dna-bindende affinitet
WO2008042814A2 (en) 2006-09-29 2008-04-10 California Institute Of Technology Mart-1 t cell receptors
EP2210903A1 (en) 2009-01-21 2010-07-28 Monoclonal Antibodies Therapeutics Anti-CD160 monoclonal antibodies and uses thereof
EP2258719A1 (en) 2009-05-19 2010-12-08 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Multiple target T cell receptor
AU2011256838B2 (en) 2010-05-17 2014-10-09 Sangamo Therapeutics, Inc. Novel DNA-binding proteins and uses thereof
US9676854B2 (en) 2011-08-15 2017-06-13 Medimmune, Llc Anti-B7-H4 antibodies and their uses
ES2728782T3 (es) 2012-05-25 2019-10-28 Univ California Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
EP3064585B1 (en) 2012-12-12 2020-02-05 The Broad Institute, Inc. Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation
AU2013361275B2 (en) 2012-12-19 2016-11-24 Amplimmune, Inc. Anti-human B7-H4 antibodies and their uses
EP3760719A1 (en) 2013-11-18 2021-01-06 CRISPR Therapeutics AG Crispr-cas system materials and methods
JP6476182B2 (ja) 2013-11-22 2019-02-27 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ 改変された高親和性ヒトt細胞受容体
EP3177314B1 (en) 2014-08-04 2020-10-07 Fred Hutchinson Cancer Research Center T cell immunotherapy specific for wt-1
TW201625689A (zh) 2014-09-12 2016-07-16 建南德克公司 抗-b7-h4抗體及免疫結合物
RU2017115315A (ru) 2014-10-03 2018-11-08 Дана-Фарбер Кэнсер Инститьют, Инк. Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения
IL254039B2 (en) 2015-02-19 2023-12-01 Compugen Ltd Anti-pvrig antibodies and methods of use
SG11201707182WA (en) 2015-03-05 2017-10-30 Hutchinson Fred Cancer Res Immunomodulatory fusion proteins and uses thereof
JO3620B1 (ar) 2015-08-05 2020-08-27 Amgen Res Munich Gmbh مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
US11047011B2 (en) 2015-09-29 2021-06-29 iRepertoire, Inc. Immunorepertoire normality assessment method and its use
WO2017112944A1 (en) * 2015-12-23 2017-06-29 Fred Hutchinson Cancer Research Center High affinity t cell receptors and uses thereof
AU2017232431A1 (en) 2016-03-15 2018-09-20 Cancer Research Technology Limited Chimeric antigen receptor
KR102397771B1 (ko) 2016-09-23 2022-05-13 프레드 헛친슨 켄서 리서치 센터 부 조직적합성(h) 항원 ha-1에 대해서 특이적인 tcr 및 이의 용도
EA201992536A1 (ru) * 2017-04-24 2020-03-05 Оспедале Сан Раффаэле С.Р.Л. Tcr и пептиды
PL3765615T3 (pl) 2018-03-14 2023-11-13 Arbor Biotechnologies, Inc. Nowe enzymy i układy crispr ukierunkowane na dna

Similar Documents

Publication Publication Date Title
JP2024074801A5 (cg-RX-API-DMAC7.html)
Houot et al. T-cell–based immunotherapy: adoptive cell transfer and checkpoint inhibition
JP2017523784A5 (cg-RX-API-DMAC7.html)
Criscitiello Tumor-associated antigens in breast cancer
Rosenberg Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens
JP7577252B2 (ja) CD300cの発現抑制剤または活性抑制剤を含む癌の予防または治療用薬学的組成物
Junghans The challenges of solid tumor for designer CAR-T therapies: a 25-year perspective
JP2022537700A5 (cg-RX-API-DMAC7.html)
Zhang et al. Genetic engineering with T cell receptors
CN113056283A (zh) 关于治疗血液肿瘤的工程化和非工程化γδ-T细胞的组合物和方法
Franks et al. New anticancer immunotherapies
CN114555815B (zh) T细胞受体及其使用方法
JP2023542528A5 (cg-RX-API-DMAC7.html)
JP2022547809A5 (cg-RX-API-DMAC7.html)
CN114450414B (zh) T细胞受体及其使用方法
JP2022506781A5 (cg-RX-API-DMAC7.html)
JP2024528029A5 (cg-RX-API-DMAC7.html)
TWI785426B (zh) 包含含有il-2蛋白及cd80蛋白之融合蛋白與自然殺手細胞的用於治療癌症的藥學組成物
AU2012281131B2 (en) Novel zinc finger-like peptide compositions as potent agents in cancer prevention and treatment
Madany et al. Immunobiology and immunotherapeutic targeting of glioma stem cells
Smith et al. Immunotherapy of colorectal cancer
JP2023526416A5 (cg-RX-API-DMAC7.html)
Subklewe Current status of immunotherapy in acute myeloid leukemia
US20180028630A1 (en) Compositions and methods for therapeutic anti-cancer vaccination
WO2026082164A1 (en) A modified dual-targeting t cell receptor complex and its pharmaceutical application thereof